802 related articles for article (PubMed ID: 32561639)
1. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
2. Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity.
Brentville VA; Metheringham RL; Gunn B; Symonds P; Daniels I; Gijon M; Cook K; Xue W; Durrant LG
Cancer Res; 2016 Feb; 76(3):548-60. PubMed ID: 26719533
[TBL] [Abstract][Full Text] [Related]
3. Homocitrullination of lysine residues mediated by myeloid-derived suppressor cells in the tumor environment is a target for cancer immunotherapy.
Cook KW; Xue W; Symonds P; Daniels I; Gijon M; Boocock D; Coveney C; Miles AK; Shah S; Atabani S; Choudhury RH; Vaghela P; Weston D; Metheringham RL; Brentville VA; Durrant LG
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321274
[TBL] [Abstract][Full Text] [Related]
4. Citrullinated Epitopes Identified on Tumour MHC Class II by Peptide Elution Stimulate Both Regulatory and Th1 Responses and Require Careful Selection for Optimal Anti-Tumour Responses.
Symonds P; Marcu A; Cook KW; Metheringham RL; Durrant LG; Brentville VA
Front Immunol; 2021; 12():764462. PubMed ID: 34858415
[TBL] [Abstract][Full Text] [Related]
5. PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy.
Choudhury RH; Symonds P; Paston SJ; Daniels I; Cook KW; Gijon M; Metheringham RL; Brentville VA; Durrant LG
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35140112
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
7. Post-translational modifications such as citrullination are excellent targets for cancer therapy.
Brentville VA; Vankemmelbeke M; Metheringham RL; Durrant LG
Semin Immunol; 2020 Feb; 47():101393. PubMed ID: 31932199
[TBL] [Abstract][Full Text] [Related]
8. Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy.
Brentville VA; Symonds P; Chua J; Skinner A; Daniels I; Cook KW; Koncarevic S; Martinez-Pinna R; Shah S; Choudhury RH; Vaghela P; Weston D; Al-Omari A; Davis J; Durrant LG
Front Immunol; 2022; 13():1066185. PubMed ID: 36544781
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
10. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
[TBL] [Abstract][Full Text] [Related]
11. Citrullinated α-enolase is an effective target for anti-cancer immunity.
Cook K; Daniels I; Symonds P; Pitt T; Gijon M; Xue W; Metheringham R; Durrant L; Brentville V
Oncoimmunology; 2018; 7(2):e1390642. PubMed ID: 29308319
[TBL] [Abstract][Full Text] [Related]
12. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
13. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
14. T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy.
Brentville VA; Symonds P; Cook KW; Daniels I; Pitt T; Gijon M; Vaghela P; Xue W; Shah S; Metheringham RL; Durrant LG
Oncoimmunology; 2019; 8(5):e1576490. PubMed ID: 31069134
[TBL] [Abstract][Full Text] [Related]
15. Broadening CD4
Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
17. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
[TBL] [Abstract][Full Text] [Related]
18. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
Assudani D; Cho HI; DeVito N; Bradley N; Celis E
Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170
[TBL] [Abstract][Full Text] [Related]
19. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
